🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fredericton
Clinical trial register · Canada

Clinical Trials in Fredericton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 2809 Montreal 1902 Vancouver 1179 Calgary 1061 Edmonton 1017
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie5 Novartis Pharmaceuticals4 Pfizer4 University of New Brunswick3 Canadian Cancer Trials Group3
Site location
Toronto2809 Montreal1902 Vancouver1179 Calgary1061 Edmonton1017
All 255 locations
Target enrolment
to

Trials with a site in Fredericton

51 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES) Study
NCT07309536Gut Microbiome, Body Composition, Adherence, Metabolites
University of New Brunswick
Not applicable
40
Fredericton
2026-10-01
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
Fredericton, Montreal
2026-09-15
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
DrugDelgocitinib
LEO Pharma
Phase 3
652
Winnipeg, Fredericton, Guelph, Newmarket, Richmond Hill, Toronto, Waterloo, Montreal
2026-05-01
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Fredericton, Hamilton, London, Québec, Verdun
2026-04-16
Recruiting
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
NCT07369076Amyotrophic Lateral Sclerosis (ALS)
Nura Bio
Phase 1/2
80
Fredericton, Toronto, Montreal
2026-03-04
Recruiting
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT07245394Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
DrugsTremfya·Guselkumab
TIDHI Innovation Inc.
Observational
200
Calgary, Fredericton, Hamilton, Barrie, Brampton, London, Mississauga, Oakville
2026-01-29
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
DrugZasocitinib
Takeda
Phase 2
90
Calgary, Fredericton, Ajax, Barrie, Newmarket, Peterborough, Montreal, Québec
2026-01-26
Recruiting
Feasibility of Aerobic Exercise With Blood Flow Restriction Training in People Living With Type 2 Diabetes
NCT07196371Type 2 Diabetes
University of New Brunswick
Not applicable
60
Okanagan, Fredericton, Guelph
2026-01-01
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
NCT07282015Hidradenitis Suppurativa
Novartis Pharmaceuticals
Observational
142
Calgary, Winnipeg, Fredericton, St. John's, Cobourg, Hamilton, London, Markham
2025-12-12
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Surrey, Fredericton, Ajax, Markham, Peterborough, Montreal, Québec
2025-12-03
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Barrie, Calgary, Fredericton, London, Québec, Red Deer, Surrey
2025-11-14
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
DrugZasocitinib
Takeda
Phase 2
200
Fredericton, Barrie, Hamilton, Oakville, Peterborough, Toronto, Québec, Saskatoon
2025-11-03
Recruiting
Mindful Moms, Mindful Meals (MMMM) Study
NCT07282964Nutrition in Early Infancy, Nutrition Habits, Postpartum Nutrition, Mindful Eating Intervention
University of New Brunswick
Not applicable
72
Fredericton
2025-09-30
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Hamilton, Markham, Waterloo
2025-09-11
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
Calgary, Edmonton, Fredericton, Barrie, London, Markham, Richmond Hill, Pointe-Claire
2025-09-02
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Calgary, Edmonton, Sherwood Park, Winnipeg, Fredericton, Barrie, Guelph, London
2025-06-27
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Fredericton, Halifax, London, Nanaimo, Ottawa, Peterborough, Sherbrooke, Thunder Bay
2025-06-16
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
573
Edmonton, Winnipeg, Fredericton, Hamilton, London, Markham, Mississauga, Saskatoon
2025-06-12
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
Calgary, Edmonton, Vancouver, Fredericton, Ajax, Markham, Mississauga, Ottawa
2025-05-14
Active, closed
Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors
NCT05470010Cancer, Psychological
Canadian Cancer Trials Group
Not applicable
300
Calgary, Kelowna, Prince George, Victoria, Brandon, Fredericton, Kingston
2025-03-07
Recruiting
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051Plaque Psoriasis, Psoriatic Arthritis
Novartis Pharmaceuticals
Not applicable
502
Calgary, Edmonton, Kelowna, Surrey, Winnipeg, Fredericton, Barrie, Greater Sudbury
2025-01-23
Recruiting
Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group
NCT05363878Alcohol Drinking, Trauma, Psychological, Historical Trauma
University of Rhode Island
Not applicable
60
Fredericton
2025-01-13
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Calgary, Edmonton, Fredericton, Toronto, Chicoutimi
2025-01-06
Recruiting
Examining the Efficacy of a Digital Media Intervention to Increase Recruitment Rates
NCT07284329Consent Process
IWK Health Centre
Not applicable
787
Edmonton, Vancouver, Fredericton, Moncton, Saint John, Saint Johns, Halifax, Kingston
2025-01-06
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Calgary, Edmonton, Kelowna, Fredericton, St. John's, Cobourg, Hamilton, London
2024-06-27
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Calgary, Edmonton, Vancouver, Winnipeg, Fredericton, Ajax, Markham, Mississauga
2024-04-29
Recruiting
A Platform Trial for Gram Negative Bloodstream Infections
NCT06537609Gram-negative Bacteremia
Sunnybrook Health Sciences Centre
Not applicable
2,500
Calgary, Edmonton, Surrey, Vancouver, Winnipeg, Fredericton, St. John's, Mississauga
2024-04-24
Recruiting
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
NCT06261021Discoid Lupus Erythematosus
DrugRuxolitinib
Innovaderm Research Inc.
Phase 2
20
Fredericton, Montreal
2024-04-19
Active, closed
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118Multiple Myeloma
DrugsIberdomide·Elranatamab
Pfizer
Phase 1
100
Fredericton, Montreal, Sherbrooke
2024-02-20
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Barrie, Hamilton, London
2024-01-30
Recruiting
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
NCT06051123ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
Centre hospitalier de l'Université de Montréal (CHUM)
Not applicable
150
Fredericton, Montreal, Saskatoon
2024-01-01
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Calgary, Surrey, Winnipeg, Fredericton, Hamilton, Waterloo, Québec, Saint-Jérôme
2023-12-19
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Calgary, Edmonton, Surrey, Fredericton, Ajax, Barrie, London, Newmarket
2023-12-12
Recruiting
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
NCT05854667Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance, Addiction
DrugLisdexamfetamine
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2
440
Vancouver, Fredericton, Toronto, Montreal
2023-12-05
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugNivolumab
Amgen
Phase 3
633
Fredericton
2023-11-02
Recruiting
Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
NCT05114096Preterm Birth, Premature Birth, Complication of Prematurity, Obstetric Labor, Premature
McMaster University
Phase 4
3,254
Calgary, Edmonton, New Westminster, Surrey, Vancouver, Victoria, Winnipeg, Fredericton
2023-07-20
Recruiting
SYNERGIC-2 Trial (SYNchronizing, Exercises and Remedies to GaIn Cognition@Home)
NCT05375513Mild Cognitive Impairment
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
250
Edmonton, Vancouver, Fredericton, London, Ottawa, Toronto, Waterloo, Montreal
2023-06-05
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
DrugsFianlimab·Cemiplimab·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,564
Fredericton, Barrie, Toronto
2023-01-16
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
696
Calgary, Edmonton, Fredericton, Kingston, London, Niagara Falls, Ottawa, Toronto
2022-12-09
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Calgary, Edmonton, Fredericton, Halifax, Toronto
2022-11-10
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672Melanoma
DrugsFianlimab·Cemiplimab·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,546
Edmonton, Fredericton, Barrie, Toronto
2022-07-14
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Calgary, Fredericton, Saint John, Hamilton, Toronto, Windsor, Montreal
2022-03-25
Active, closed
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
NCT05081557Atopic Dermatitis
AbbVie
Observational
873
Edmonton, Winnipeg, Fredericton, St. John's, Cobourg, Greater Sudbury, Hamilton, Markham
2021-11-17
Recruiting
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
NCT04151342Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related
University Health Network, Toronto
Observational
5,500
Calgary, Edmonton, Vancouver, Winnipeg, Fredericton, St. John's, Halifax, Brampton
2020-01-17
Active, closed
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057106Lung Cancer Metastatic
DrugsTremelimumab·Durvalumab
Canadian Cancer Trials Group
Phase 2
301
Edmonton, Surrey, Vancouver, Fredericton, Moncton, Saint John, Cambridge, Greater Sudbury
2017-03-28
Recruiting
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group
Phase 3
614
Edmonton, Surrey, Vancouver, Victoria, Fredericton, Barrie, Greater Sudbury, Hamilton
2016-10-31
Active, closed
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Alliance for Clinical Trials in Oncology
Phase 3
3,177
Abbotsford British Columbia, Victoria, Brandon, Fredericton, Moncton, Saint John, St. John's, Barrie
2016-09-16
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707Community-acquired Pneumonia, Influenza, COVID-19
DrugsConvalescent plasma·DMX-200·Ivermectin·Amoxicillin-clavulanate
UMC Utrecht
Phase 3
20,000
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Brampton, Brantford, Hamilton
2016-04-11
Active, closed
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405Prostatic Neoplasms
DrugsLhrha·Enzalutamide
University of Sydney
Phase 3
1,125
Calgary, Edmonton, Surrey, Vancouver, Winnipeg, Fredericton, Saint John, Halifax
2014-03
Active, closed
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Edmonton, New Westminster, Surrey, Vancouver, Victoria, Fredericton, Halifax, Brampton
2013-04-29
Active, closed
Psoriasis Longitudinal Assessment and Registry
NCT00508547Psoriasis
Janssen Scientific Affairs, LLC
Observational
20,167
Calgary, Edmonton, Nanaimo, Surrey, Vancouver, Winnipeg, Fredericton, Moncton
2007-06-21
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-canada/city/fredericton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Fredericton.

How many clinical trials are recruiting in Fredericton?

27 of the 51 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 1 have not yet opened recruitment, 22 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fredericton), 51 studies
PhaseStudiesRecruitingShare
Phase 320739.2%
Not applicable10819.6%
Phase 29617.6%
Observational8415.7%
Phase 4213.9%
Phase 1102%
Phase 1/2112%

Most active sponsors

Lead sponsors with the most studies (Fredericton)
Lead sponsorStudiesRecruiting
AbbVie51
Novartis Pharmaceuticals43
Pfizer41
Canadian Cancer Trials Group31
University of New Brunswick32
Apogee Therapeutics, Inc.21
Centre hospitalier de l'Université de Montréal (CHUM)22
Incyte Corporation20
LEO Pharma22
Regeneron Pharmaceuticals20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.